Patients with previously treated metastatic lung adenocarcinoma face a well-recognized therapeutic limitation once platinum-based chemotherapy and immune checkpoint inhibitors (ICIs) have been exhausted.
Beyond these standards, available options historically provide:
- Modest response rates
- Short disease control
- Limited survival extension
As a result, there has been increasing interest in microenvironment-directed combination strategies, particularly those integrating:
- Immune checkpoint blockade, which restores antitumor T-cell activity
- Anti-angiogenic therapy, which can reduce VEGF-mediated immune suppression, normalize tumor vasculature, and potentially re-sensitize tumors to immunotherapy
Within this evolving framework, combining nivolumab with the multitarget anti-angiogenic tyrosine kinase inhibitor nintedanib represents a biologically rational attempt to overcome acquired resistance after prior systemic therapy.
Metastatic Lung Cancer: Causes, Symptoms, Treatment, and 2025 Advances in Therapy
Study Design
This investigation was conducted as a multicenter, open-label, single-arm phase Ib/II trial enrolling patients with advanced (stage IIIB/IV) lung adenocarcinoma who had already received one or two prior systemic treatment lines, including platinum-based chemotherapy with or without previous exposure to immune checkpoint inhibitors.
A conventional 3+3 dose-escalation strategy was used to determine the recommended phase II dose of the nivolumab–nintedanib combination.
Beyond dose finding, the study was designed to characterize three core clinical dimensions:
- Safety and tolerability of the combined immune–antiangiogenic approach
- Disease control durability, assessed through progression-free survival at 6 and 9 months
- Biomarker-associated survival patterns, with particular attention to PD-L1 expression and FGFR1 signaling status, both of which may influence responsiveness to therapy
Together, this framework aimed not only to establish feasibility, but also to explore whether biologic stratification could identify patients most likely to benefit from this combination strategy.
Recommended Dose and Safety
The combination proved clinically feasible at:
- Nintedanib 200 mg twice daily
- Nivolumab 240 mg every two weeks
Importantly, no new safety signals were observed, confirming that dual immune-angiogenic targeting can be delivered without unexpected toxicity in pretreated patients.
Opdivo (Nivolumab): Uses in Cancer, Side Effects, Dosages, Expectations, and More
Clinical Activity
Disease Control
At the recommended phase II dose, the nivolumab–nintedanib combination demonstrated measurable but limited disease stabilization in this heavily pretreated population.
Approximately one quarter of patients remained progression-free at six months, while around 10% maintained progression-free status at nine months, indicating that a subset of tumors achieved meaningful short-term control despite prior treatment exposure.
Overall Survival
Median overall survival was approximately 12 months, though outcomes varied markedly according to underlying tumor biology.
Long-term survival at 36 months reached nearly 70% in tumors with high PD-L1 expression, compared with about 40% in tumors characterized by both low PD-L1 and low FGFR1 expression.
In contrast, low PD-L1 tumors with high FGFR1 signaling were associated with distinctly poorer survival outcomes.
Taken together, these findings emphasize that clinical benefit from combined immune checkpoint inhibition and anti-angiogenic therapy is strongly shaped by the interaction between immune activation and angiogenic signaling pathways, rather than by PD-L1 status alone.
Immune Checkpoint Rechallenge
A particularly interesting signal emerged in patients previously treated with checkpoint inhibitors.
These individuals showed longer survival than checkpoint-naïve patients, suggesting that:
- Resistance to immunotherapy may not be permanent
- Anti-angiogenic therapy could help restore immune sensitivity
This concept is becoming increasingly relevant across modern immunotherapy sequencing strategies.
Biological Interpretation
Several important biological insights emerge from this study.
First, immune–angiogenic combinations do not appear to generate uniform benefit across all patients, yet carefully defined biological subgroups may achieve clinically meaningful long-term survival. This reinforces the growing recognition that treatment efficacy in advanced lung cancer is increasingly context-dependent rather than universal.
Second, the data suggest that FGFR-driven tumor biology may contribute to immune resistance, highlighting FGFR signaling as a potential mechanistic barrier to effective checkpoint inhibition. In this context, FGFR blockade through agents such as nintedanib may function as a rational partner to immunotherapy, particularly in tumors characterized by angiogenic or growth-factor–mediated immune suppression.
Third, the observation that patients previously exposed to checkpoint inhibitors derived improved outcomes upon rechallenge supports the evolving concept that tumor microenvironmental state—rather than prior treatment exposure alone—determines renewed immunotherapy sensitivity. This aligns with broader evidence that immune resistance can be dynamic and potentially reversible.
Clinical Meaning
Taken together, these findings position the combination of nivolumab plus nintedanib as a strategy that is clinically feasible and safe in pretreated lung adenocarcinoma, with modest overall activity but meaningful potential in biomarker-defined subgroups.
Importantly, the regimen may offer a mechanism-based opportunity to re-sensitize tumors to immunotherapy, particularly in patients with prior checkpoint exposure. Rather than serving as a universal treatment approach, this combination is better understood as a precision-oriented therapeutic option that may benefit carefully selected patients defined by immune and angiogenic biology.
Key Takeaway Messages
- The nivolumab–nintedanib combination is feasible and well tolerated in previously treated lung adenocarcinoma.
- Overall efficacy is limited, but durable survival emerges in biologically defined subgroups.
- High PD-L1 expression and prior checkpoint exposure appear to predict the greatest benefit.
- FGFR signaling may represent an important resistance pathway influencing outcomes.
- Future development should focus on biomarker-driven patient selection and immunotherapy rechallenge strategies rather than broad, unselected use.
Read Full article here